Search Contract Opportunities

access to national-level pharmaceutical sales data and International level sales data to estimate and forecast trends in pharmaceutical sales, pricing, and volume of distribution throughout various settings of care.

ID: 75F40122R00082 • Type: Synopsis Solicitation • Match:  90%
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Please sign-in to link federal registration and award history to assistant. Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Do the documents mention an incumbent contractor?
I'd like to anonymously submit a question to the procurement officer(s)

Description

Posted: Sept. 1, 2022, 2:59 p.m. EDT

FDA/CDER requires access to national-level pharmaceutical sales data and international-level pharmaceutical sales data to estimate and forecast trends in pharmaceutical sales, pricing, and volume of distribution throughout various settings of care. Continued access to these data allows the FDA to respond expeditiously to questions relating to drug safety, the impact of regulatory policies, and to potential drug shortage situations, helping the Agency to make more informed decisions about matters that affect the health of Americans.

See Attachments for RFP and related attachments.

Modification:

See attachment for Contractor Questions and Government Responses.

Bassed on the Contractor Questions, the Description Title for this requirement has been updated and the Solictation Document has been updated. Please see the document "Solcitation updated 9 1 2022..."

Posted: Aug. 30, 2022, 10:37 a.m. EDT
Show All

Overview

Agency
Center for Drug Evaluation and Research (CDER) [HHS - FDA]
Response Deadline
Sept. 9, 2022, 2:00 p.m. EDT Past Due
Posted
Aug. 30, 2022, 10:37 a.m. EDT (updated: Sept. 1, 2022, 2:59 p.m. EDT)
Set Aside
None
NAICS
518210 - Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services
PSC
B529 - Special Studies/Analysis- Scientific Data
Place of Performance
Silver Spring, MD 20903 United States
Source
Open
Current SBA Size Standard
$40 Million
Pricing
Fixed Price
Evaluation Criteria
Best Value
On 8/30/22 Center for Drug Evaluation and Research issued Synopsis Solicitation 75F40122R00082 for access to national-level pharmaceutical sales data and International level sales data to estimate and forecast trends in pharmaceutical sales, pricing, and volume of distribution throughout various settings of care. due 9/9/22. The opportunity was issued full & open with NAICS 518210 and PSC B529.
Primary Contact
Name
Howard S. Yablon   Profile
Email
howard.yablon@fda.hhs.gov
Phone
(240) 402-7630

Documents

Posted documents for Synopsis Solicitation 75F40122R00082

Question & Answer

The AI Q&A Assistant has moved to the bottom right of the page

Contract Awards

Prime contracts awarded through Synopsis Solicitation 75F40122R00082

Incumbent or Similar Awards

Potential Bidders and Partners

Awardees that have won contracts similar to Synopsis Solicitation 75F40122R00082

Similar Active Opportunities

Open contract opportunities similar to Synopsis Solicitation 75F40122R00082

Additional Details

Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > FOOD AND DRUG ADMINISTRATION > FDA CENTER FOR DRUG EVALUATION AND RESEARCH
FPDS Organization Code
7524-75DKKN
Source Organization Code
500024274
Last Updated
Sept. 1, 2022
Last Updated By
howard.yablon@fda.hhs.gov
Archive Date
Sept. 24, 2022